MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Ovarian cancer diagnosis and treatment
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,301 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,301 works in the cohort · of 4,299,418page 26 of 47

Labels cover 7 of 2,301 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,301 of 2,301 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affvenueunlabeled
Diagnosing ovarian cancer
Melissa Walker, Mara Sobel
2018· article· en· Canadian Medical Association Journal· Medicine
machine prediction:candidate · noneconsensus · none
5
citations
venueno affunlabeled
Ovarian cancer screening
D.M. Allen
2005· letter· en· Canadian Medical Association Journal· Medicine
machine prediction:candidate · noneconsensus · none
5
citations
affno abstractunlabeled
Other New Targets
Helen Mackay, Amit M. Oza
2009· review· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
5
citations
affno abstractunlabeled
Authors’ Response
Caroline Reinhold, Elizabeth A. Sadowski, Andrea Rockall, Isabelle Thomassin‐Naggara
2021· letter· en· Journal of the American College of Radiology· Medicine
machine prediction:candidate · noneconsensus · none
5
citations
affunlabeled
Efficacy and safety of luveltamab tazevibulin vs investigator’s choice of chemotherapy in patients with recurrent platinum-resistant ovarian cancer (PROC) expressing folate receptor alpha (FRα): The REFRaME-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase 2/3 study.
Ana Oaknin, Jung-Yun Lee, David Cibula, Yeh Chen Lee, Russell J. Schilder, Annika Auranen +13 more
2024· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
5
citations
affno abstractunlabeled
Primary malignant mesodermal ovarian sarcomas
Abdulgafour Gari, Luís Souhami, Jocelyne Arseneau, G. Stanimir
2006· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
5
citations

How this was built: Screen · Findings · About